Clinical Trial


Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg


Brief description

The purpose of this study is to evaluate the lung function response to UMEC/VI, UMEC, and VI in individual patients using a cross-over design. This is a multicenter, randomized, double-blind, 3-way crossover study. Eligible subjects will be randomized to a sequence of UMEC 62.5mcg, VI 25mcg, and UMEC/VI 62.5/25mcg. All subjects will receive each treatment once-daily for 14 days, and each treatment will be separated by a 10-14 day washout period. There will be a 5-7 day run-in period prior to randomization.

Keywords

  •   Pulmonary Disease, Chronic Obstructive

Sponsored By

GlaxoSmithKline

Unique Study ID

NCT01716520

Investigators and Research Sites Near You - Found( 2 )

No Investigator Listed

GlaxoSmithKline
90502, Haapsalu, Estonia
Distance from Current Trial is 0 miles

No Investigator Listed

GlaxoSmithKline
90502, Haapsalu, Estonia
Distance from Current Trial is 0 miles
View All